About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Suven Life Sciences Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
03-Nov-2025
11-Nov-2025
Quarterly Results
05-Aug-2025
13-Aug-2025
Quarterly Results
06-May-2025
13-May-2025
Preferential Issue of shares & Issue Of Warrants & Audited Results
16-Jan-2025
24-Jan-2025
Quarterly Results
21-Oct-2024
29-Oct-2024
Quarterly Results
29-Jul-2024
05-Aug-2024
Quarterly Results
29-Apr-2024
06-May-2024
Audited Results
23-Jan-2024
30-Jan-2024
Quarterly Results
27-Oct-2023
04-Nov-2023
Quarterly Results
01-Aug-2023
08-Aug-2023
Quarterly Results
02-May-2023
09-May-2023
Quarterly Results & Audited Results
25-Jan-2023
02-Feb-2023
Quarterly Results
03-Nov-2022
10-Nov-2022
Quarterly Results
07-Oct-2022
12-Oct-2022
Right Issue of Equity Shares
18-Jul-2022
26-Jul-2022
Quarterly Results
20-Jun-2022
24-Jun-2022
Rights Issue & Inter alia, to consider matters related to raising of funds through issue of equity shares of the Company on rights basis to the existing equity shareholders of the Company in accordance with provisions of Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other matters related/ incidental thereto including the constitution of a Committee of Board of Directors namely ?Rights Issue Committee? to implement the proposal of Rights Issue.
02-May-2022
07-May-2022
Audited Results
24-Jan-2022
31-Jan-2022
Quarterly Results
18-Oct-2021
25-Oct-2021
Quarterly Results
02-Aug-2021
09-Aug-2021
Quarterly Results
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.